Oncogenic role of SIRT1 associated with tumor invasion, lymph node metastasis, and poor disease-free survival in triple negative breast cancer

2015 ◽  
Vol 33 (2) ◽  
pp. 179-185 ◽  
Author(s):  
Soo Young Chung ◽  
Yoon Yang Jung ◽  
In Ae Park ◽  
Hyojin Kim ◽  
Yul Ri Chung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Tumor Invasion ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Free Survival ◽  
Node Metastasis ◽  
Disease Free

scholarly journals Clinicopathological Significance of TARBP2, APP, and ZNF395 in Breast Cancer

2016 ◽  
Vol 10 ◽  
pp. BCBCR.S40820
Author(s):  
Ryoko Oi ◽  
Hirotaka Koizumi ◽  
Ichiro Maeda ◽  
Akira Noguchi ◽  
Shinobu Tatsunami ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Disease Free Survival ◽  
Clinicopathological Parameters ◽  
Free Survival ◽  
Expression Levels ◽  
Node Metastasis ◽  
Disease Free

The double-stranded RNA-binding protein TARBP2 has been suggested to act as an upstream regulator of breast cancer metastasis by destabilizing transcripts of the possible metastasis suppressors amyloid precursor protein (APP) and ZNF395. We examined this hypothesis by immunostaining of TARBP2, APP, and ZNF395 in 200 breast cancer specimens using tissue microarrays and analyzed the relationships between expression levels and clinicopathological parameters and prognosis. Increased TARBP2 overexpression was associated with shorter overall survival and disease-free survival, and increased but not reduced APP expression correlated with lower overall survival and disease-free survival. ZNF395 expression levels had no prognostic value, but reduced expression correlated with reduced lymph node metastasis. There was no significant relationship between TARBP2 overexpression and reduced APP and/or ZNF395 expression. Patients with tumors with higher TARBP2 or APP expression had unfavorable prognoses. Although reduced ZNF395 expression was significantly related to reduced lymph node metastasis, further studies are needed to clarify the role of TARBP2/APP/ZNF395 in breast cancer.

scholarly journals Survival Study of Triple-Negative and Non–Triple-Negative Breast Cancer in a Brazilian Cohort

2018 ◽  
Vol 12 ◽  
pp. 117955491879056 ◽  
Author(s):  
Homero Gonçalves ◽  
Maximiliano Ribeiro Guerra ◽  
Jane Rocha Duarte Cintra ◽  
Vívian Assis Fayer ◽  
Igor Vilela Brum ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Lymph Node Involvement ◽  
Free Survival ◽  
Node Involvement ◽  
Brazilian Cohort ◽  
Disease Free

Objective: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Brazilian cohort and identify potential prognostic factors. Methods: This hospital-based retrospective cohort study included 447 women with breast cancer treated at referral centers in Southeastern Brazil. Overall and disease-free survival were compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 19.5% of breast cancer diagnosis and was more prevalent among nonwhite and less educated women. The patients with TNBC tended to present with stage III cancer, high p53 expression, lymphocytic infiltration, and multifocality and treated with radical surgery and chemotherapy. The 5-year overall and disease-free survival were 62.1% and 57.5% for TNBC and 80.8% and 75.3% for non-TNBC, respectively ( P < .001). The TNBC recurrence was associated with multicentricity, whereas lymph node involvement increased the risk of both recurrence and death. Non-TNBC worse clinical course was associated with nonwhite ethnicity, lower education level, lymph node involvement, and advanced stage. Conclusions: Triple-negative breast cancer exhibited a more aggressive behavior, earlier and more frequent recurrence, and worse survival compared with non-TNBC. While biological and social variables were associated with poorer prognosis in non-TNBC, only lymph node involvement and multicentricity were correlated with worse clinical outcomes in TNBC.

scholarly journals Overexpression of HHLA2 is Markedly Associated with the Poor Prognosis in Medullary Thyroid Carcinoma

2021 ◽  
Author(s):  
Yongzhi Niu ◽  
Wei Wang ◽  
Xiaodan Jiang ◽  
Jisheng Zhang ◽  
Yichuan Huang ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Disease Free Survival ◽  
Free Survival ◽  
Medullary Thyroid ◽  
Node Metastasis ◽  
Tumor Tissues ◽  
Disease Free

Abstract Human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) is a newly identified immune checkpoint molecule that was aberrantly expressed in many malignant tumors. However, its expression in medullary thyroid carcinoma (MTC) is still unclear. This study aimed to investigate the HHLA2 expression in MTC tissues and to evaluate the relationships between its expression and clinicopathologic together with prognostic relevance. Using 51 surgical specimens obtained from MTC patients, the expression levels of the HHLA2 protein in MTC tumor tissues and adjacent noncancerous tissues were measured by immunohistochemistry, and its correlations with clinicopathologic and prognostic features were analyzed. Status of CD8+ tumor-infiltrating lymphocytes (TILs) was also investigated. The results showed that HHLA2 was only detected in tumor tissues, and that 31.4% of the MTC patients had high expression of HHLA2. High HHLA2 expression was significantly associated with lymph node metastasis and advanced AJCC stages (P=0.005). There existed an inverse trend between HHLA2 expression and CD8+ TILs infiltration in MTC tumor samples (P=0.042). The log-rank test showed a shorter disease-free survival in patients with high HHLA2 expression (P=0.002). The disease-free survival rates were also significantly low in cases of MTC with lymph node metastasis, AJCC stages III-IV and multifocality. Multivariate Cox analysis confirmed that HHLA2 acted as an independent predictive factor in the disease-free survival of MTC patients (HR=4.138, 95%CI: 1.027-16.667, P=0.046). Taken together, HHLA2 is highly expressed in MTC patients, and is a poor prognostic biomarker of disease-free survival of MTC patients.

scholarly journals The effect of lymph node metastasis on overall survival and disease-free survival in vulvar cancer patients

2020 ◽  
Vol 91 (2) ◽  
pp. 62-67
Author(s):  
Volkan Karataşlı ◽  
Selçuk Erkılınç ◽  
İlker Çakır ◽  
Behzat Can ◽  
Tuğba Karadeniz ◽  
...  
Keyword(s):  
Overall Survival ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Cancer Patients ◽  
Vulvar Cancer ◽  
Disease Free Survival ◽  
Free Survival ◽  
Node Metastasis ◽  
Disease Free

Lymphatic metastasis in well-differentiated appendiceal cancer: Prognostic factors and associations with outcome.

2012 ◽  
Vol 30 (4_suppl) ◽  
pp. 406-406
Author(s):  
Joshua S. Hill ◽  
Safia Rafeeq ◽  
Matthew H.G. Katz ◽  
Michael J. Overman ◽  
Laura A. Lambert ◽  
...  
Keyword(s):  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Disease Free Survival ◽  
Nodal Metastasis ◽  
Free Survival ◽  
Node Metastasis ◽  
Increased Risk ◽  
Well Differentiated ◽  
Disease Free

406 Background: Well-differentiated appendiceal adenocarcinomas (WDAA) are rare tumors characterized by peritoneal spread. Lymph node metastasis can occur, yet the association between nodal spread and recurrence is poorly understood. Methods: A single institution retrospective review of patients seen between August 1993 and January 2010 with a pathologic diagnosis of WDAA who underwent colectomy was conducted. Patients with zero lymph nodes found during pathologic review were excluded. Parameters evaluated included demographics, presence of lymph node metastasis, completeness of cytoreduction and time to recurrence. Results: Of 688 patients with appendiceal neoplasms, 160 (23.3%) had WDAA. The mean age at diagnosis was 50.7 years and 81 (50.6%) were male. Median follow-up after diagnosis was 58.5 months. One hundred patients (62.5%) had regional or distant metastasis present at the time of colectomy. Seventy-eight (48.8%) colectomies were performed at outside institutions. The median number of nodes examined was 12. Twelve patients (7.5%) were found to have nodal metastasis. The rate of peritoneal metastasis did not correlate with the presence of nodal metastasis (node positive 9/12, 75% versus node negative 91/148, 61.5%; p=0.35). No difference in the ability to perform complete cytoreduction existed for those with and without nodal metastasis (66% versus 51% p=0.19). Examining patients with complete cytoreduction and ≥ 12 months of follow-up, there was an increased risk of recurrence among patients with lymphatic metastasis compared to those without (5/8, 62.5% versus 15/61, 24.6%; p=0.03). In this subset, median disease-free-survival in lymph node positive patients was 53 months compared to 109.1 months in patients without nodal metastasis (p=0.08). Conclusions: Patients with WDAA tumors have an overall favorable prognosis; however, patients with lymph node metastasis appear to have an increased risk of recurrence and apparent shortened disease free survival. Right colectomy may be warranted in this patient population.

Triple-negative and non–triple-negative breast cancer in a south Indian cohort.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e13110-e13110
Author(s):  
Narayanankutty Edavalath Warrier ◽  
Uma V Sankar ◽  
Sreedharan P S ◽  
Ajmal Sherif
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Triple Negative Breast Cancer ◽  
Rural Women ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Lymph Node Involvement ◽  
Free Survival ◽  
Node Involvement ◽  
Disease Free

e13110 Background: The heterogeneity of breast cancer explains in part the differences in the morbidity and mortality of this disease. Triple-negative breast cancer (TNBC) is a specific subset of tumors characterized by the absence of the 3 most commonly targeted biomarkers considered for breast cancer treatment: Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2). TNBC accounts for 15% to 20% of all breast cancer diagnoses and usually has a more aggressive clinical course, with worse evolution within the first 3 to 5 years after diagnosis; early and higher rates of distant recurrences, typically visceral; and poor survival. Methods: To analyze the clinical, pathological, and sociodemographic aspects between triple-negative breast cancer (TNBC) and non-TNBC in a Kerala cohort and identify potential prognostic factors. This hospital-based retrospective cohort study (From January 2017 till December 2018) included 465 women with breast cancer treated at MVR Cancer Centre & Research Institute in North Kerala. Overall and disease-free survival was compared; prognostic factors were evaluated. Results: Triple-negative breast cancer corresponded to 16.3% of breast cancer diagnosis and was more prevalent among rural women. The patients with TNBC tended to present with stage III cancer, high p53 expression, lymphocytic infiltration, and multifocality and treated with radical surgery and chemotherapy. The 2-year overall and disease-free survival were 52.1% and 43.5% for TNBC and 83.8% and 73.4% for non-TNBC, respectively ( P < .001). The TNBC recurrence was associated with multicentricity, whereas lymph node involvement increased the risk of both recurrence and death. Non-TNBC worse clinical course was associated with rural women, younger age, lymph node involvement, and advanced stage. Conclusions: Triple-negative breast cancer exhibited a more aggressive behavior, earlier and more frequent recurrence, and worse survival compared with non-TNBC. While biological and social variables were associated with poorer prognosis in non-TNBC, only lymph node involvement and multicentricity were correlated with worse clinical outcomes in TNBC.

Sign in / Sign up

Export Citation Format

Share Document